Successful people in any human endeavor are disciplined. Each has at least an operating strategy which he or she believes in and sticks to even in the face of unpalatable situations. Clay B. Siegall, from all indications, falls into this category.
I was not surprise to hear him revealed his strategy for life and business; no one with his kind of achievements lacks such. For the lay man, he put it this way: “Learn as much as you can; interact with very smart people who have expertise in many areas.” He modified same and made it his company strategy: “An important component of our business strategy is collaborating with other industry leaders and innovators in oncology drug development.” The bottom line is that he believes no man has a monopoly of knowledge and that one can be better of by collaborating with others. Instances where he put this strategy to work abounds.
Clay B. Siegall had the best of training as a scientist with focus on targeted cancer therapies and a Ph.D. in Genetics from George Washington University. He co-founded Seattle Genetics in 1998 and became the company’s President, Chief Executive Officer and Board Chairman since then. Today, the company is known for scientific innovation, rigorous research, drug development practices and undying passion for helping cancer patients. The company has come up with a good number of antibody-drug conjugates (ADCs) over the years. ADCETRIS® (brentuximab vedotin), the first of the pack, got the nod of the FDA in 2011. With the collaboration of Takeda Pharmaceutical Company and Seattle Genetics, the drug has now turned a global brand as over 65 countries currently use it in treating their cancer patients.
It cost much financing ADC technology, so the company has to enter into multiple strategic licenses. Currently the company is in corporate agreements with a number of companies including Pfizer, AbbVie, GlaxoSmithKline and Genetics (Roche) amassing well beyond $350 million to date. Seattle Genetics’ numerous internal and collaborator programs has also paid off as over 20 ADCs are in clinical development with the aid of the company’s technology.
Clay B. Siegall is indisputably a viable weapon for the eventual eradication of cancer. For a man to have 15 patents to his name is no mean feat.